AGILE GROUP (03383) had a total pre-sale amount of approximately 4.67 billion yuan in the first eight months, a decrease of 25.52% year-on-year.
Aijiake Group (03383) announced that the pre-sale amount for the Group, along with its joint ventures and associates, as well as real estate projects managed by the Group and sold under the "Aijiake" brand (Aijiake projects), totaled approximately RMB 380 million in August 2026, a year-on-year decrease of 34.48%; the corresponding construction area was approximately 46,000 square meters; the average price was RMB 8,234 per square meter.
AGILE GROUP (03383) announced that the total presale amount of the group, along with its joint ventures and associates, and the real estate projects managed by the group and sold under the "Agile" brand (Agile projects), was approximately RMB 380 million in August 2026, a year-on-year decrease of 34.48%; the corresponding area was approximately 46,000 square meters; the average price was RMB 8,234 per square meter.
For the eight months ending August 31, 2026, the total presale amount of the group, along with its joint ventures and associates, and the Agile projects was approximately RMB 4.67 billion, a year-on-year decrease of 25.52%; the corresponding area was approximately 520,000 square meters; the average price was RMB 8,977 per square meter.
Related Articles

Jiangsu Hengrui Pharmaceuticals (01276): SHR-1179 Injection has obtained the Clinical Trial Approval Notification.

Nanchang Jiahui, a shareholder of Jiangxi Guoke Defence Group (688543.SH), intends to reduce its holdings by no more than 3%.

Ningbo Cixing (300307.SZ) plans to repurchase company shares for 100 million to 120 million yuan.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-1179 Injection has obtained the Clinical Trial Approval Notification.

Nanchang Jiahui, a shareholder of Jiangxi Guoke Defence Group (688543.SH), intends to reduce its holdings by no more than 3%.

Ningbo Cixing (300307.SZ) plans to repurchase company shares for 100 million to 120 million yuan.

RECOMMEND





